BIOND BIOLOGICS
Biond Biologics is a discovery and development company in the prosperous and evolving field of cancer immunotherapy and autoimmune disorders. Biond aims to translate high quality science into breakthrough therapies that will address unmet medical needs while focusing on innovative drugs. Biond is an Israeli company located at Galilee region, combining excellent science and out of the box innovation.
BIOND BIOLOGICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-04-21
Address:
Misgav, HaZafon, Israel
Country:
Israel
Website Url:
http://www.biondbio.com
Total Employee:
11+
Status:
Active
Contact:
+972-4-8844337
Email Addresses:
[email protected]
Total Funding:
32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Similar Organizations
Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
MigVax
MigVax is an Israeli medical technology startup.
NaturNorth Technologies
NaturNorth Technologies is a pioneering biotech discovery and development company.
Sciwind Biosciences
Sciwind Biosciences is a drug research and development company for metabolic diseases.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Deep Insight
Deep Insight investment in Series C - Biond Biologics
Heritage Group
Heritage Group investment in Series C - Biond Biologics
Harel Insurance Investments and Financial Services
Harel Insurance Investments and Financial Services investment in Series C - Biond Biologics
Harel Insurance Investments and Financial Services
Harel Insurance Investments and Financial Services investment in Series B - Biond Biologics
Celgene
Celgene investment in Series B - Biond Biologics
Israel Biotech Fund
Israel Biotech Fund investment in Series B - Biond Biologics
SBI Japan-Israel Innovation Fund
SBI Japan-Israel Innovation Fund investment in Series B - Biond Biologics
Official Site Inspections
http://www.biondbio.com Semrush global rank: 3.68 M Semrush visits lastest month: 3.81 K
- Host name: israel15.jetserver.net
- IP address: 81.218.83.71
- Location: Jerusalem Israel
- Latitude: 31.7808
- Longitude: 35.2287
- Timezone: Asia/Jerusalem
More informations about "Biond Biologics"
About Biond Biologics – Biond Biologics
Biond is an innovative clinical stage biotech company developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for the treatment of cancer patients.See details»
Biond Biologics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +972-4-8844337 Biond Biologics is a discovery and development company in the prosperous and …See details»
Leadership – Biond Biologics
Tehila is the Co-Founder of Biond. She has served as Biond’s CEO and Board of Directors chairperson since the company’s inception. Tehila brings over a decade of scientific …See details»
Biond Biologics Company Profile | Management and Employees …
Www.biondbio.com Biond Biologics Profile and History Biond Biologics is a drug discovery and development company focused on developing innovative therapies for novel oncology targets …See details»
BION-206 - Drug Targets, Indications, Patents - Synapse - Patsnap
Jan 25, 2025 Originator Organization. Biond Biologics Ltd. Startup. Active Organization. Biond Biologics Ltd. Startup. Inactive Organization ... in many cancers. Company contact: Tal Sines …See details»
Biond Biologics Ltd | LinkedIn
It appear to be PhD season at Biond Biologics... We would like to congratulate Yair Harel for receiving his PhD degree from the Weizmann Institute of Science. Weizmann Alumni …See details»
Biond Biologics CEO and Key Executive Team | Craft.co
Biond Biologics's Co-Founder, Chairperson & Chief Executive Officer is Tehila Ben Moshe. Other executives include Ori Shilo, Co-Founder & Chief Financial Officer; Yair Sapir, Chief Operation …See details»
Sanofi : Biond Biologics and Sanofi Enter into Global Licensing ...
Jan 12, 2021 "We are thrilled to partner with Sanofi, an organization with a global footprint and exceptional drug development and commercialization capabilities," said Ori Shilo, Co-Founder …See details»
BND-22 - Drug Targets, Indications, Patents - Synapse - Patsnap
Active Organization-Inactive Organization. Biond Biologics Ltd. Startup. Drug Highest Phase Pending Phase 2. First ... in many cancers. Company contact: Tal Sines VP of Business …See details»
Biond Biologics and Sanofi Enter into Global Licensing Agreement …
Jan 12, 2021 Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor Biond to receive $125 million …See details»
Immuno-Oncology – Biond Biologics
BND-22, a novel, first-in-class immune checkpoint inhibitor targeting the ILT2 (LILRB1) receptor which was partnered with Sanofi and is currently being studied in a phase 1 clinical trialSee details»
Biond Biologics to Regain Full Rights to BND-22, a Novel Immune ...
Mar 3, 2025 www.biondbio.com. Company contact: Tal Sines VP Business Development Biond Biologics Ltd. +972-4 884 4337 [email protected] SOURCE Biond Biologics Ltd. WANT YOUR …See details»
Biond Biologics Announces Closing of $15 Million Series C Financing
Nov 3, 2021 For more information, visit www.biondbio.com. About Deep Insight Fund. Deep Insight is the first Israeli venture fund to invest only in Deep Tech at all stages and across all …See details»
Biond Biologics and Sanofi Enter into Global Licensing Agreement …
Mar 4, 2021 MISGAV, Israel, Jan. 12, 2021 /PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a privately-held biopharmaceutical company, developing novel immunotherapies …See details»
BND-22, a first-in-class humanized ILT2-blocking antibody
4 Oncology Reseach, Sanofi, Cambridge, Massachusetts, USA [email protected] [email protected]. PMID: 36096532; PMCID: PMC9472153 DOI: 10.1136/jitc-2022 …See details»
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical …
Biond announced on January 12th, 2021 an exclusive worldwide license agreement with Sanofi, for the development and commercialization of BND-22. Under the terms of the agreement, …See details»
7 Organizational Structure Types (With Examples) - Forbes
May 29, 2024 A hierarchical organization structure is the pyramid-shaped organization chart many people are used to seeing. There is one role at the top of the pyramid and the chain of …See details»
Clinical Trials – Biond Biologics
If you are a medical professional and require further information about Biond Biologics, our clinical research, or clinical trials, please send an email to [email protected]. BND-35-001 It is a …See details»
Biond Biologics to Regain Full Rights to BND-22, a Novel Immune ...
Mar 3, 2025 www.biondbio.com. Company contact: Tal Sines VP Business Development Biond Biologics Ltd. +972-4 884 4337 [email protected] SOURCE Biond Biologics Ltd.See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»